Incidence and outcomes of atrial fibrillation and systolic dysfunction in patients receiving mavacamten for obstructive hypertrophic cardiomyopathy: A multicenter study

Authors

• Olives Nguyen, Knight Cardiovascular Institute, Oregon Health & Science University, Portland, OR, USA.
• Jack Wiedrick, Knight Cardiovascular Institute, Oregon Health & Science University, Portland, OR, USA.
• Daniele Massera, NYU Langone, New York, NY, USA.
• Elizabeth Adlestein, NYU Langone, New York, NY, USA.
• Sumar Frejat, NYU Langone, New York, NY, USA.
• Matteo Castrichini, Mayo Clinic, Rochester, MN, USA; Phoenix, AZ, USA.
• Said Alsidawi, Mayo Clinic, Rochester, MN, USA; Phoenix, AZ, USA.
• John R. Giudicessi, Mayo Clinic, Rochester, MN, USA; Phoenix, AZ, USA.
• Jeffrey B. Geske, Mayo Clinic, Rochester, MN, USA; Phoenix, AZ, USA.
• Richard T. Carrick, Johns Hopkins University, Baltimore, MD, USA.
• Jose Madrazo, Johns Hopkins University, Baltimore, MD, USA.
• Nicole Dellise, Ascension Saint Thomas Heart West, Nashville, TN, USA.
• Mark A. Zenker, Ascension Saint Thomas Heart West, Nashville, TN, USA.
• Thomas A. Boyle, University of Pennsylvania, Philadelphia, PA, USA.
• Nosheen Reza, University of Pennsylvania, Philadelphia, PA, USA.
• Anjali Tiku Owens, University of Pennsylvania, Philadelphia, PA, USA.
• David S. Frankel, University of Pennsylvania, Philadelphia, PA, USA.
• Prabhjot Hundal, Advocate Health - MidwestFollow
• Jamil Tajik, Advocate Health - MidwestFollow
• Patrycja Galazka, Advocate Health - MidwestFollow
• et al

Recommended Citation

Nguyen O, Wiedrick J, Massera D, et al. Incidence and Outcomes of Atrial Fibrillation and Systolic Dysfunction in Patients Receiving Mavacamten for Obstructive Hypertrophic Cardiomyopathy: A Multicenter Study. J Card Fail. Published online March 1, 2026. doi:10.1016/j.cardfail.2026.02.035

Affiliations

Aurora St. Luke's Medical Center

Type

Article

PubMed ID

41775292